No Data
Selected Announcement | China Petroleum & Chemical Corporation: The net income in the first three quarters was 44.247 billion yuan, a year-on-year decrease of 16.5%; Beijing Oriental Yuhong Waterproof Technology: planning to invest 0.5 billion yuan to -1
Three Squirrels Inc. plans to increase investment in building snack supply chain and intensive bases.
Shanghai Laishi: Report for the third quarter of 2024
shanghai raas blood products (002252.SZ): net income for the first three quarters was 1.838 billion yuan, a year-on-year increase of 2.81%.
GeLongHui October 28th | Shanghai RAAS Blood Products (002252.SZ) released the third quarter report for 2024, achieving revenue of 6.314 billion yuan in the first three quarters, a year-on-year increase of 6.39%; net income attributable to the shareholders of the listed company was 1.838 billion yuan, a year-on-year increase of 2.81%; net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 1.739 billion yuan, a year-on-year decrease of 3.64%; basic earnings per share was 0.277 yuan.
Express News | Raas Blood Products Q3 Net Profit up 8.8% Y/Y
shanghai raas blood products (002252.SZ): As of now, the company and its subsidiaries, affiliates own a total of 44 single plasma stations.
October 18th, RASS (002252.SZ) accepted a specific investigation on October 18, 2024, regarding the "new plasma station situation of the company?", the company stated that as one of the leading domestic blood product enterprise, plasma source development is one of the company's key priorities, which adheres to the dual focus of stock and increment. On one hand, it continues to strengthen the potential of existing plasma sources, promoting the internal growth of plasma stations by enhancing the management of current plasma stations; on the other hand, it actively promotes the opening up of plasma stations, strives for incremental breakthroughs, and maintains the continuous development of the company's plasma collection business. As of now, the company and its subsidiaries,
shanghai raas blood products (002252.SZ): The clinical indications of high concentration albumin and 5% albumin are basically the same.
On October 18, Grancool reported that shanghai raas blood products (002252.SZ) received specific research on October 18, 2024, regarding the "Situation of High-Concentration Intravenous Prothrombin Complex?". The company stated that the clinical indications of high-concentration intravenous prothrombin complex are basically the same as 5% prothrombin complex, but the infusion time in clinical settings is slightly reduced.
No Data
No Data